Biohaven Pharmaceutical Holding Shares Outstanding 2016-2022 | BHVN

Biohaven Pharmaceutical Holding shares outstanding history from 2016 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Biohaven Pharmaceutical Holding shares outstanding for the quarter ending March 31, 2022 were 0.070B, a 13.36% increase year-over-year.
  • Biohaven Pharmaceutical Holding 2021 shares outstanding were 0.065B, a 10.12% increase from 2020.
  • Biohaven Pharmaceutical Holding 2020 shares outstanding were 0.059B, a 21.12% increase from 2019.
  • Biohaven Pharmaceutical Holding 2019 shares outstanding were 0.048B, a 23.74% increase from 2018.
Biohaven Pharmaceutical Holding Annual Shares Outstanding
(Millions of Shares)
2021 65
2020 59
2019 48
2018 39
2017 28
2016 13
2015 11
Biohaven Pharmaceutical Holding Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 70
2021-12-31 65
2021-09-30 65
2021-06-30 65
2021-03-31 62
2020-12-31 59
2020-09-30 60
2020-06-30 59
2020-03-31 56
2019-12-31 48
2019-09-30 52
2019-06-30 45
2019-03-31 44
2018-12-31 39
2018-09-30 40
2018-06-30 39
2018-03-31 37
2017-12-31 28
2017-09-30 36
2017-06-30 26
2017-03-31 13
2016-12-31 13
2016-09-30 13
2016-06-30 13
2016-03-31 12
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.366B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.995B 9.34
GSK (GSK) United Kingdom $82.506B 9.91
Bio-Rad Laboratories (BIO.B) United States $16.008B 35.37
QIAGEN (QGEN) Netherlands $11.286B 18.90
Ginkgo Bioworks Holdings (DNA) United States $5.454B 0.00
Arcus Biosciences (RCUS) United States $1.972B 38.49
Emergent Biosolutions (EBS) United States $1.578B 9.15
Myovant Sciences (MYOV) United Kingdom $1.450B 0.00
Zymeworks (ZYME) Canada $0.376B 0.00
Enzo Biochem (ENZ) United States $0.123B 0.00
Gelesis Holdings (GLS) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
Ambrx Biopharma (AMAM) United States $0.091B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00